| Mrs Elizabeth Neugart Coronado, MD | |
|
3809 W 15th St, Bldg 700, Suite A, Plano, TX 75075-1601 | |
| (972) 379-2416 | |
| (972) 867-1018 |
| Full Name | Mrs Elizabeth Neugart Coronado |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 23 Years |
| Location | 3809 W 15th St, Plano, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154340628 | NPI | - | NPPES |
| 943177 | Medicaid | AZ | |
| 8J3718 | Other | TX | MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | M4743 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical City Plano | Plano, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Women's Specialists Of Plano, L.l.p. | 3779742903 | 7 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP).
For more than 20 years, doctors have been using cells from blood that remains in the placenta and umbilical cord after childbirth to treat a variety of illnesses, from cancer and immune disorders to blood and metabolic diseases.
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.
As India urgently scales up its vaccination campaign for the COVID-19 virus, a new study which examined the country's successful program to eliminate polio provides guidance on how this and future mass immunization campaigns can be successful, especially in vaccinating hard to reach groups.
› Verified 4 days ago
| Entity Name | Women's Specialists Of Plano, L.l.p. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811988116 PECOS PAC ID: 3779742903 Enrollment ID: O20120307000954 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP).
For more than 20 years, doctors have been using cells from blood that remains in the placenta and umbilical cord after childbirth to treat a variety of illnesses, from cancer and immune disorders to blood and metabolic diseases.
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.
As India urgently scales up its vaccination campaign for the COVID-19 virus, a new study which examined the country's successful program to eliminate polio provides guidance on how this and future mass immunization campaigns can be successful, especially in vaccinating hard to reach groups.
› Verified 4 days ago
| Entity Name | Obhg Texas Holdings Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083917769 PECOS PAC ID: 3577713072 Enrollment ID: O20121018000279 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP).
For more than 20 years, doctors have been using cells from blood that remains in the placenta and umbilical cord after childbirth to treat a variety of illnesses, from cancer and immune disorders to blood and metabolic diseases.
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.
As India urgently scales up its vaccination campaign for the COVID-19 virus, a new study which examined the country's successful program to eliminate polio provides guidance on how this and future mass immunization campaigns can be successful, especially in vaccinating hard to reach groups.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Elizabeth Neugart Coronado, MD 3809 W 15th St, Bldg 700, Suite A, Plano, TX 75075-1601 Ph: (972) 379-2416 | Mrs Elizabeth Neugart Coronado, MD 3809 W 15th St, Bldg 700, Suite A, Plano, TX 75075-1601 Ph: (972) 379-2416 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP).
For more than 20 years, doctors have been using cells from blood that remains in the placenta and umbilical cord after childbirth to treat a variety of illnesses, from cancer and immune disorders to blood and metabolic diseases.
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.
As India urgently scales up its vaccination campaign for the COVID-19 virus, a new study which examined the country's successful program to eliminate polio provides guidance on how this and future mass immunization campaigns can be successful, especially in vaccinating hard to reach groups.
› Verified 4 days ago
Dr. Christy Washington Walker, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 6130 W Parker Rd Ste 204, Plano, TX 75093 Phone: 972-981-7861 Fax: 972-981-7862 | |
Surekha Machupalli, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 8901 Independence Pkwy, Plano, TX 75025 Phone: 972-908-2444 | |
Dr. Arlene Esther Garcia-soto, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6957 W Plano Pkwy Ste 2000, Plano, TX 75093 Phone: 214-483-6933 Fax: 214-483-6648 | |
Dr. Katrina H Walsh, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1600 Coit Rd, Suite 402, Plano, TX 75075 Phone: 972-519-1900 Fax: 972-964-5323 | |
Dr. Nora L Hsu, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5425 W Spring Creek Pkwy Ste 280, Plano, TX 75024 Phone: 972-867-6400 | |
Madhuri Gudipaty, M.D Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1600 Coit Rd, Suite 101, Plano, TX 75075 Phone: 972-867-7500 Fax: 972-578-7550 | |
Carol L. Brown-elliott, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3901 W 15th St, #200, Plano, TX 75075 Phone: 972-519-1328 |